Goodwin Advises Merida Biosciences in up to $2.875 Billion Acquisition by Eli Lilly

The Life Sciences team advised Merida Biosciences in a definitive agreement to be acquired by Eli Lilly and Company (Lilly) (NYSE: LLY) for up to $2.875 billion in cash, inclusive of an upfront payment and contingent milestone payments. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026. The acquisition strengthens Lilly’s immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need.

Merida Biosciences is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.

The Goodwin team was led by Laura Gulick, Sarah Solomon, Kimberley Maruncic, Dylan Miller, Jennifer Ford, Elizabeth Mulkey, Billy Hubbard, Hugh Rennie, John Vernaglia, and Kingsley Taft and included Grace Wirth, James Oh, Dan Karelitz, Chase Gorland, Jennifer Fay, Anna Shipley Roy, Arman Oruc, Eram Khan, and Daniel Farraye.

For more information on the deal, please read the press release.

Goodwin Advises Merida Biosciences in up to $2.875 Billion Acquisition by Eli Lilly

Related Content

FDA approves Regeneron’s PASATRU™ (garetosmab-grts) for Fibrodysplasia Ossificans Progressiva

FDA Addresses FAQs on Developing Potential Cellular and Gene Therapy Products

Takeda Files BPCIA Suit Against Polpharma Biologics For Vedolizumab Biosimilar

Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK

Biocon Launches Aflibercept Biosimilar in the United States

$46 Million Veloxis Settlement Yields Record Sunshine Penalty and Insights Into DOJ’s Cross-Agency Data Use

Deadline Approaching: OIG Seeks Input on Anti-Kickback Safe Harbors for Clinical Trial Participant Remuneration

FDA Approves Moderna’s mFLUSIVA (mRNA-1010) Seasonal Influenza Vaccine

Goodwin Pharma Services Symposium

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Advises Aureka Biotechnologies on Intellectual Property Aspects for $100 Million Series B

Goodwin Advises Amylyx Pharmaceuticals on $575 Million Public Offering

Goodwin Advises AbCellera Biologics on $200 Million Public Offering

Goodwin Advises Fulcrum Therapeutics on Merger with Slate Medicines and $245 Million Private Placement Financing

Goodwin Advises the Underwriters on Silence’s $201 Million Public Offering

Goodwin Advises Zealand Pharma on Entering Into a $100 Million Royalty Purchase and Sale Agreement With Royalty Pharma for the Economics Related to rusfertide

Life Sciences